GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Centessa Pharmaceuticals PLC (STU:260) » Definitions » Pretax Margin %

Centessa Pharmaceuticals (STU:260) Pretax Margin % : % (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Centessa Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Centessa Pharmaceuticals's Pre-Tax Income for the three months ended in Mar. 2024 was €-34.56 Mil. Centessa Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €0.00 Mil. Therefore, Centessa Pharmaceuticals's pretax margin for the quarter that ended in Mar. 2024 was %.

The historical rank and industry rank for Centessa Pharmaceuticals's Pretax Margin % or its related term are showing as below:

STU:260' s Pretax Margin % Range Over the Past 10 Years
Min: -2570.28   Med: -2570.28   Max: -2388.28
Current: -2388.28


STU:260's Pretax Margin % is ranked worse than
82.61% of 1018 companies
in the Biotechnology industry
Industry Median: -154.275 vs STU:260: -2388.28

Centessa Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Centessa Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centessa Pharmaceuticals Pretax Margin % Chart

Centessa Pharmaceuticals Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Pretax Margin %
- - - - -2,570.35

Centessa Pharmaceuticals Quarterly Data
Dec19 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Pretax Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - -520.85 -

Competitive Comparison of Centessa Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Centessa Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Centessa Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Centessa Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Centessa Pharmaceuticals's Pretax Margin % falls into.



Centessa Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Centessa Pharmaceuticals's Pretax Margin for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Margin=Pre-Tax Income (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=-161.521/6.284
=-2,570.35 %

Centessa Pharmaceuticals's Pretax Margin for the quarter that ended in Mar. 2024 is calculated as

Pretax Margin=Pre-Tax Income (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-34.56/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Centessa Pharmaceuticals  (STU:260) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.


Centessa Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Centessa Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Centessa Pharmaceuticals (STU:260) Business Description

Traded in Other Exchanges
Address
1 Ashley Road, 3rd Floor, Altrincham, Cheshire, GBR, WA14 2DT
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.

Centessa Pharmaceuticals (STU:260) Headlines

No Headlines